Drug intelligence / Profile preview

VxD-001

Development stage: Unknown
Lead developer: Vaxdyn
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

VxD-001 is a prophylactic vaccine candidate developed by Vaxdyn in collaboration with Reig Jofre Group. It is designed to prevent infections caused by multi-drug resistant (MDR) *Acinetobacter baumannii*, a Gram-negative bacterium identified by the World Health Organization as a critical priority pathogen. The vaccine utilizes a platform technology that targets conserved surface proteins of the bacteria to elicit a broad and protective immune response. Supported by funding from CARB-X, the program aims to address the high mortality and morbidity associated with hospital-acquired infections caused by antibiotic-resistant strains. As of 2024, the vaccine is in Phase 1 clinical development.

Other names: Acinetobacter baumannii vaccine

Targets

A. baumannii (Acinetobacter baumannii)

Beyond the preview

Go deeper on VxD-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VxD-001.

Explore the full profile